Australia markets open in 6 hours 14 minutes

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
38.57+0.11 (+0.29%)
At close: 04:00PM EDT
37.13 -1.44 (-3.73%)
After hours: 07:49PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 4.90B
Enterprise value 6.06B
Trailing P/E 18.37
Forward P/E 12.61
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.24
Price/book (mrq)58.47
Enterprise value/revenue 7.31
Enterprise value/EBITDA 13.42

Trading information

Stock price history

Beta (5Y monthly) 1.25
52-week change 318.20%
S&P500 52-week change 322.36%
52-week high 345.00
52-week low 329.85
50-day moving average 339.79
200-day moving average 338.84

Share statistics

Avg vol (3-month) 31.02M
Avg vol (10-day) 3721.51k
Shares outstanding 5127.05M
Implied shares outstanding 6127.05M
Float 8125.47M
% held by insiders 11.08%
% held by institutions 1100.29%
Shares short (15 Apr 2024) 48.24M
Short ratio (15 Apr 2024) 48.73
Short % of float (15 Apr 2024) 48.78%
Short % of shares outstanding (15 Apr 2024) 46.48%
Shares short (prior month 15 Mar 2024) 48.2M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 33.96%
Operating margin (ttm)45.01%

Management effectiveness

Return on assets (ttm)11.89%
Return on equity (ttm)222.07%

Income statement

Revenue (ttm)829.25M
Revenue per share (ttm)6.29
Quarterly revenue growth (yoy)26.70%
Gross profit (ttm)N/A
EBITDA 416.93M
Net income avi to common (ttm)281.59M
Diluted EPS (ttm)2.10
Quarterly earnings growth (yoy)48.00%

Balance sheet

Total cash (mrq)336M
Total cash per share (mrq)2.65
Total debt (mrq)1.53B
Total debt/equity (mrq)1,827.33%
Current ratio (mrq)6.64
Book value per share (mrq)0.66

Cash flow statement

Operating cash flow (ttm)388.57M
Levered free cash flow (ttm)268.16M